Clinical Scorecard: Single- and multi-tablet HIV regimens go head-to-head
At a Glance
| Category | Detail |
|---|---|
| Condition | HIV |
| Key Mechanisms | Viral suppression defined as HIV RNA level below 200 copies/mL. |
| Target Population | Adults with HIV enrolled in Washington state Medicaid. |
| Care Setting | HIV treatment and management in Medicaid programs. |
Key Highlights
- 90.4% of Medicaid enrollees achieved viral suppression.
- No statistically significant difference in suppression rates between single-tablet and multi-tablet regimens.
- Housing status significantly impacts viral suppression rates.
- Bictegravir/emtricitabine/tenofovir alafenamide is 77% more expensive than some multi-tablet alternatives.
- Cost considerations should be integrated into treatment decisions.
Guideline-Based Recommendations
Diagnosis
- Viral suppression should be monitored as a key outcome in HIV treatment.
Management
- Consider both cost and patient preferences when selecting HIV regimens.
Monitoring & Follow-up
- Regular assessment of housing stability as it correlates with treatment adherence.
Risks
- Unstable housing is associated with lower rates of viral suppression.
Patient & Prescribing Data
Adults with HIV in Washington state Medicaid.
Single-tablet regimens may not provide significant clinical advantages over multi-tablet regimens.
Clinical Best Practices
- Integrate cost information into treatment decision-making.
- Address social determinants of health, such as housing stability, in treatment plans.
- Encourage adherence strategies that consider patient circumstances.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
